NEXT BIOTECH

CPH is targeting US growth through M&A - Seeking a CEO

Today Creso Pharma’s (ASX:CPH) announced the acquisition of a range of CBD brand and product assets that deliver anti-inflammatory relief to professional and amateur athletes suffering from chronic muscle and joint pain.

DXB announces approval for Phase III COVID-19 trials

On Friday last week, DXB announced that the main drug regulator in India has recommended approval for DXB’s Phase III clinical trials on COVID-19 treatment, specifically for patients with respiratory complications intended for hospitalisation — its CLARITY 2.0 study.

Market responding well to Psychedelics for mental health progress

CPH yesterday went on to announce the successful grant of a rare “Controlled Drugs and Substances license” licence for Haluenex in Canada, another positive step in their psychedelics story.

Introducing: Our Biotech Pick of the Year 2021

Today we announce the fourth addition to our portfolio for 2021. Today we are adding Dimerix (ASX:DXB) to the Next Investors portfolio as our inaugural Biotech Pick of the Year for 2021.

CPH releases material announcement

Creso Pharma Ltd (ASX:CPH | OTC:COPHF) has just confirmed two consecutive quarters of record revenue growth. CPH posted $1.71M revenue this quarter - up from $1.38M in the previous quarter - that’s 24% growth.

What We DO and DON’T like about the proposed CPH Merger

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

CPH’s US listing is happening tonight - trading as OTC: COPHF

Creso Pharma (ASX:CPH) today announced its listing in the US, and the market is opening in around 12 hours - the US pool of investors is huge and they have a big appetite for psychedelics and cannabis stocks.

CPH just picked up 10 grams of pharma grade psilocybin

Creso Pharma (ASX: CPH)’s acquisition target Halucenex just picked up an extra 10g of ‘hard-to-access’ synthetic psilocybin - and now has 22.3g in total.

The NASDAQ Listing We Will be Watching Tonight

Creso Pharma (ASX: CPH) is listing on the US markets within weeks (via an OTC listing), but a similar company called MindMed is listing on the NASDAQ in 8 hours from now.

We Participated in the CPH placement - and so did Billionaire John Hancock

Creso Pharma (ASX: CPH) is edging closer to becoming part of our long term portfolio. CPH just raised $18M, which significantly shores up the balance sheet - another tick in the box for us as CPH builds trust to enter our long term portfolio.

SURPRISE: We are Now Psychedelics Investors

Once again, medicinal cannabis company Creso Pharma (ASX: CPH) keeps pleasantly surprising us. Today they have REALLY surprised us by announcing they have acquired a Psychedelics company.

CPH to be the First ASX Stock to Acquire 100% of a Psychedelics Company

Creso Pharma (ASX: CPH) will be the first ASX listed stock to acquire 100% of a psychedelics company. CPH is set to acquire Canada based Halucenex Life Sciences Inc., an established psychedelics company developing treatments for a range of mental illnesses.

CPH deliver Financials and Confirms US Cannabis Market Entry

Creso Pharma (ASX: CPH) just released its preliminary financial reports for the year, which as expected show a bunch of impairments, debt clean ups and other scary looking one off costs that come with a balance sheet clean up - these are all out of the way now.

CPH Confirms US Cannabis Market Entry with Established Partner - US$5M Sales Target

Creso Pharma (ASX: CPH | FRA: 1X8) is set to distribute its range of CBD and hemp animal health anibidiol® products throughout the US, following a deal signed with CERES Natural Remedies.

The CPH Share Price Seems to Have Stabilised – What’s Next?

Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

What’s Happening to the CPH Share Price?

Over recent days, Creso Pharma (ASX: CPH) appears to have gained some significant momentum. Momentum includes three new purchase orders for Creso Pharma’s anibidiol® line of animal health products were signed today, to a value of $A$414,000.

Short Term Trade Update: What’s Happening to the CPH Share Price?

We put out a short note on Creso Pharma (ASX: CPH) to some of you that might have previously invested in the stock and not had a positive experience. After a couple of false starts, our plan is to ride this momentum over the coming weeks and hopefully recoup some of our previous losses.

Canopy Growth Founder Joins a Refreshed, Re-Set and Re-Funded CPH

While Creso Pharma (ASX: CPH) continues to sign purchase orders and has appointed Bruce Linton as an advisor, it is a highly speculative investment, and our intent is to hold for the coming months through to Christmas to see how the company’s strategy plays out.

Are you a sophisticated investor?
Find out more
Please note: Raisebook is a related entity of S3 Consortium Pty Ltd as defined in Section 9 of the Corporations Act 2001.

Thanks for subscribing!

X